Literature DB >> 1490778

Drug utilization research in primary health care as exemplified by physicians' quality assessment groups.

L von Ferber1, A Luciano, I Köster, J Krappweis.   

Abstract

Drugs in primary health care are often prescribed for nonrational reasons. Drug utilization research investigates the prescription of drugs with an eye to medical, social and economic causes and consequences of the prescribed drug's utilization. The results of this research show distinct differences in drug utilization in different age groups and between men and women. Indication and dosage appear irrational from a textbook point of view. This indicates nonpharmacological causes of drug utilization. To advice successfully changes for the better quality assessment groups of primary health care physicians get information about their established behavior by analysis of their prescriptions. The discussion and the comparisons in the group allow them to recognize their irrational prescribing and the social, psychological and economic reasons behind it. Guidelines for treatment are worked out which take into account the primary health care physician's situation. After a year with 6 meetings of the quality assessment groups the education process is evaluated by another drug utilization analysis on the basis of the physicians prescription. The evaluation shows a remarkable improvement of quality and cost effectiveness of the drug therapy of the participating physicians.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1490778

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  2 in total

Review 1.  Strategies for improving prescribing practice.

Authors:  G M Anderson; J Lexchin
Journal:  CMAJ       Date:  1996-04-01       Impact factor: 8.262

2.  Pharmacotherapeutic circles. Results of an 18-month peer-review prescribing-improvement programme for general practitioners.

Authors:  L von Ferber; J Bausch; I Köster; I Schubert; P Ihle
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.